Form 4: X4 Pharmaceuticals CFO Adam S. Mostafa Receives 850,000 Restricted Stock Units

Adam S. Mostafa, CFO of X4 Pharmaceuticals, was granted 850,000 restricted stock units under the company's equity incentive plan.

Summary

• Adam S. Mostafa, the Chief Financial Officer of X4 Pharmaceuticals, received 850,000 restricted stock units on February 12, 2025.
• The grant was made under the Issuer's Amended and Restated 2017 Equity Incentive Plan.
• Each restricted stock unit represents the right to receive one share of common stock on the applicable vesting date.
• No amount was paid upon the grant of the restricted stock units.
• The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to continued employment with X4 Pharmaceuticals.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock units is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. There are no explicitly negative aspects mentioned.

Positives

• The grant of restricted stock units aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Risks

• The vesting of the restricted stock units is contingent upon the CFO's continued employment, creating a potential risk if he were to leave the company before the vesting dates.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, focusing instead on the details of the restricted stock unit grant.

Industry Context

Grants of restricted stock units are a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives.

Stakeholder Impact

• The grant of restricted stock units could have a positive impact on shareholders by aligning management's interests with the company's long-term success.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates